Results 191 to 200 of about 13,617 (225)
Some of the next articles are maybe not open access.
Drugs, 2001
* Omalizumab is a recombinant humanised monoclonal antibody which specifically binds to the C epsilon3 domain of immunoglobulin (Ig) E, the site of high-affinity IgE receptor binding. * Improvements in asthma symptoms and health-related quality-of-life, and a significant reduction in the frequency of asthma exacerbations were seen in allergic asthmatic
S, Easthope, B, Jarvis
openaire +3 more sources
* Omalizumab is a recombinant humanised monoclonal antibody which specifically binds to the C epsilon3 domain of immunoglobulin (Ig) E, the site of high-affinity IgE receptor binding. * Improvements in asthma symptoms and health-related quality-of-life, and a significant reduction in the frequency of asthma exacerbations were seen in allergic asthmatic
S, Easthope, B, Jarvis
openaire +3 more sources
New England Journal of Medicine, 2006
A 16-year-old boy with a history of severe persistent asthma despite treatment with inhaled corticosteroids presents for evaluation. Treatment with omalizumab, a monoclonal anti-IgE antibody, is recommended. This agent has been found to reduce the frequency of exacerbations of asthma in clinical trials.
Robert C, Strunk, Gordon R, Bloomberg
openaire +2 more sources
A 16-year-old boy with a history of severe persistent asthma despite treatment with inhaled corticosteroids presents for evaluation. Treatment with omalizumab, a monoclonal anti-IgE antibody, is recommended. This agent has been found to reduce the frequency of exacerbations of asthma in clinical trials.
Robert C, Strunk, Gordon R, Bloomberg
openaire +2 more sources